Olopatadine 0.6% Nasal prep

Indications

Olopatadine 0.6% Nasal prep is used for: Allergic rhinitis

Adult Dose

Nasal Seasonal allergic rhinitis Adult: As 0.6% spray: 2 sprays into each nostril bid. Child: 6-11 yr 1 spray into each nostril bid.

Child Dose

Nasal Seasonal Allergic Rhinitis <6 years: Safety and efficacy not established 6-12 years: 1 spray each nostril twice daily. >12 years: 2 sprays each nostril twice daily.

Renal Dose

Administration

Priming: Before initial use, prime Nasal Spray by releasing 5 sprays or until a fine mist appears. When Nasal Spray has not been used for more than 7 days, re-prime by releasing 2 sprays.

Contra Indications

It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.

Precautions

Patients should be informed to avoid spraying Nasal Spray in their eyes. Patient w/ other nasal disease. Patient Counselling May impair ability to engage in activities requiring complete mental alertness and motor coordination (e.g. driving or operating machinery) after admin of the nasal spray. Nasal examinations should be performed periodically for signs of adverse effects on the nasal mucosa. Lactation: Unknown whether distributed in breast milk, caution advised

Pregnancy-Lactation

Interactions

May result in additive CNS depression w/ CNS depressants.

Side Effects

Side effects of Olopatadine 0.6% Nasal prep : >10% Bitter taste (12.8%; 1% pediatric), Respiratory epistaxis (3-25%) 1-10% Headache (4.4%), Depression (2%), Fatigue (1%), Somnolence (1%), Weight gain (1%), Epistaxis (3.2%; 5.7% pediatric), Upper respiratory tract infection (2.6% pediatric), Pharyngolaryngeal pain (2.2%), Postnasal drip (1.5%), Cough (1.4%), Urinary tract infection (1.2%), Upper respiratory tract infection in children (3%) <1% CPK elevation, Dry mouth, Anosmia, Hyposmia, Nasopharyngitis, Throat irritation, Influenza

Mode of Action

Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.